SUNPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | SUNPHARMA | Market Cap | 4,18,434 Cr. | Current Price | 1,744 ₹ | High / Low | 1,851 ₹ |
| Stock P/E | 95.9 | Book Value | 99.2 ₹ | Dividend Yield | 0.92 % | ROCE | 16.8 % |
| ROE | 17.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,743 ₹ | DMA 200 | 1,712 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.60 % | PAT Qtr | 872 Cr. | PAT Prev Qtr | 564 Cr. |
| RSI | 46.2 | MACD | 18.7 | Volume | 23,54,189 | Avg Vol 1Wk | 24,30,736 |
| Low price | 1,547 ₹ | High price | 1,851 ₹ | PEG Ratio | 1.31 | Debt to equity | 0.56 |
| 52w Index | 64.9 % | Qtr Profit Var | -24.6 % | EPS | 16.7 ₹ | Industry PE | 27.2 |
SUNPHARMA (Sun Pharmaceutical Industries Ltd) shows strong fundamentals in terms of ROE (17.8%) and ROCE (16.8%), supported by consistent profitability and a large market cap. However, the stock trades at a very high valuation (P/E 95.9 vs industry PE 27.2), which limits upside potential. The PEG ratio (1.31) suggests moderate growth relative to price, while dividend yield (0.92%) provides limited income support. Recent profit decline (-24.6% QoQ) raises caution for long-term investors.
📈 Ideal Entry Price Zone
An attractive entry zone would be between ₹1,600–₹1,680, closer to the 200 DMA (₹1,712) and below the current price (₹1,744). This range offers better valuation comfort given stretched multiples.
📊 Exit Strategy / Holding Period
If already holding, investors should adopt a long-term horizon (3–5 years) due to strong fundamentals and sectoral growth prospects. Exit strategy may be considered near ₹1,850–₹1,900 (recent highs) if earnings growth does not justify the premium valuation. Otherwise, holding is advisable for compounding returns in the pharmaceutical sector.
✅ Positive
- Strong ROE (17.8%) and ROCE (16.8%) indicate efficient capital use
- Large market cap (₹4,18,434 Cr) ensures stability and leadership
- Quarterly PAT growth from ₹564 Cr to ₹872 Cr shows operational strength
- DII holdings increased (+0.60%), reflecting domestic institutional confidence
⚠️ Limitation
- Extremely high P/E ratio (95.9) compared to industry PE (27.2)
- PEG ratio of 1.31 suggests valuation is ahead of growth
- Dividend yield of 0.92% is modest
- Book value (₹99.2) far below current price (₹1,744), indicating stretched valuation
📰 Company Negative News
- Quarterly profit variation shows decline (-24.6%)
- FII holdings decreased (-0.43%), signaling reduced foreign investor confidence
🌟 Company Positive News
- Strong PAT growth in recent quarter (₹872 Cr vs ₹564 Cr)
- MACD positive (18.7), suggesting bullish momentum
🏦 Industry
- Pharmaceutical industry benefits from long-term demand and global healthcare expansion
- Industry PE (27.2) is significantly lower than SUNPHARMA’s PE, highlighting premium valuation
🔎 Conclusion
SUNPHARMA is a fundamentally strong company but trades at stretched valuations. Entry near ₹1,600–₹1,680 offers better risk-reward balance. Long-term investors (3–5 years) can hold for compounding, but exits near ₹1,850–₹1,900 should be considered if earnings growth fails to justify the premium.